Faculty Collaboration Database

Hemophilia factor VIII therapy. Immunological tolerance. A clinical perspective. Haematologica 2000 Oct;85(10 Suppl):113-6

Date

02/24/2001

Pubmed ID

11187862

Scopus ID

2-s2.0-0034302623 (requires institutional sign-in at Scopus site)   7 Citations

Abstract

Human alloantibodies to factor VIII occur in 15-50% of patients with severe hemophilia A. The development of these inhibitory alloantibodies prevents treatment with replacement factor VIII and places the patient at higher risk for complications from bleeding. Immune tolerance to factor VIII can be achieved in patients with inhibitors through the regular administration of factor VIII. The mechanism by which immune tolerance is achieved is unclear but the regular administration of factor VIII is believed to interrupt the normal immune mechanisms, perhaps by altering antigen presentation and inducing T or B cell anergy. The development of immune tolerance in hemophilia can be seen as a potential model for the development of methods for inducing tolerance to other alloimmune and autoimmune disorders.

Author List

White GC 2nd, Greenwood R, Escobar M, Frelinger JA

Author

Gilbert C. White MD Professor in the Medicine department at Medical College of Wisconsin

MESH terms used to index this publication - Major topics in bold

Factor VIII
Hemophilia A
Humans
Immune Tolerance
Isoantibodies
Lymphocyte Activation